Haemonetics (HAE) Misses Q2 EPS by 1c, Lowers FY EPS Guidance
Tweet
Share
E-mailGet Alerts HAE Hot Sheet
Price: $108.40 +0.74%
Revenue Growth %: +5.5%
Financial Fact:
Net revenues: 220.25M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Revenue Growth %: +5.5%
Financial Fact:
Net revenues: 220.25M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Haemonetics (NYSE: HAE) reported Q2 EPS of $0.60, $0.01 worse than the analyst estimate of $0.61. Revenue for the quarter came in at $239.9 million versus the consensus estimate of $239.99 million.
GUIDANCE:
Haemonetics sees FY2022 EPS of $2.40-$2.65, versus the consensus of $2.76.
For earnings history and earnings-related data on Haemonetics (HAE) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Citi upgrades Haemonetics to Buy, raises price target to $123
- Redburn upgrades Southwest, stays bullish on Delta and United
- UBS Reiterates Neutral Rating on Intuit (INTU), Says Investor Day Not 'Sentiment-Changing'
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
